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A CLINICOPATHOLOGICAL COHORT STUDY OF LIVER PATHOLOGY IN 301 PATIENTS 
WITH HIV/AIDS 
 
Introduction: Globally approximately 34 million people are HIV infected with sub-Saharan Africa 
disproportionately affected. Whilst HIV itself causes no direct liver disease, consequences 
secondary to HIV are common.  Liver pathology data is limited and findings differ between high, 
middle and low-income countries.  In the era of highly active antiretroviral therapy (HAART), 
morbidity and mortality due to liver disease has emerged as a significant issue.  The spectrum of 
liver pathology and disease in patients with HIV/AIDS in South Africa, the epicentre of the 
pandemic, is largely unknown.  
 
Aim: To determine the spectrum and clinicopathological correlates of liver pathology in patients 
with HIV/AIDS in a dedicated liver clinic and referral centre in a middle and low-income country.  
 
Methods:  A database of all liver biop ies performed in HIV positive patients since January 2000 
was established in 2005.  Patients were included retro- and prospectively.  Clinical and 
demographic data including age, gender, WHO clinical stage, CD4 cell count, hepatitis B and C 
status, complete drug history prior to biopsy, liver chemistry and tissue culture results, amongst 
others, were recorded.  All liver biopsies were assessed by one of two experienced liver 
pathologists.  Statistical comparisons were performed using the Fisher’s exact, Chi-squared and 
Mann-Whitney U-test and where indicated, odds ratios were calculated.  Multivariate logistic 
regression analysis was performed to identify factors associated with specific patterns of drug 













Results: 301 patients, median age 34 (IQR 29-40) years were evaluated including 158 men, 
median age 35 years (IQR 31-41) and 143 woman, median age 33 years (IQR 28-37), P=0.001.  
Ethnically, 76.1%, 11.6%, 11.6% and <1% were black African, Caucasian, Mixed Ancestry and 
Asian/Indian, respectively.  Median CD4 cell count at time of liver biopsy was 127 (52-260) and not 
significantly different between men 118 (46-249) and women 132 (55-270), P=0.56.  Drug induced 
liver injury (DILI) was observed in 127 (42.2%) patients with patterns of drug injury including non-
specific hepatitis 51(40.2%), cholestasis 20 (15.7%), mixed hepatitis-cholestatic 25 (19.7%), 
steatohepatitis 5 (4%), vanishing bile duct syndrome 11 (8.6%), submassive necrosis 13 (10.2%) 
and granulomatous 2 (1.6%).  Of the patients with DILI, 85 (67%) used cotrimoxazole, 78 (61%) 
HAART and 41 (32.2%) TB drugs either individually or in combination.  Other implicated drugs 
were fluconazole 9 (7%) and herbal toxins 8 (6%).  With univariate analysis, cotrimoxazole and 
HAART conferred risk for a DILI (OR 2.78 (1.72-4.48), P<0.001, OR 1.69 (1.06-2.68), P=0.027, 
respectively), but anti-TB drugs did not (OR 0.68 (0.42-1.09), P=0.112).  With multivariate logistic 
regression analysis, cotrimoxazole predicted strongly for cholestatic and ductopenic injury, whilst 
efavirenz was mostly associated with non-specific hepatitis and submassive necrosis.  Female 
gender predicted for cholestatic injury, whilst a CD4 cell count >200 and younger age predicted for 
submassive necrosis.   A total of 86 (29%) patients had granulomatous inflammation, mostly non-
necrotizing (92%) and predominantly due to Mycobacterium tuberculosis.  Hepatitis B was the 
prevalent viral hepatitis observed in 56 (19%) with PCR confirmed hepatitis C noted in only 10 
(3.3%) patients.  Steatosis/steatohepatitis was observed in 58 (19.3%).  Notably, 16.2% of the 
cohort had >1 histopathological finding. 
Conclusion: In this large cohort of patients with mostly advanced HIV/AIDS, DILI was the 
dominant pathological process with cotrimoxazole and HAART, mostly efavirenz and nevirapine, 
conferring a significant risk.  Although TB drugs likely also confer risk; significance is influenced by 
selection bias for liver biopsy in the study.  Tuberculosis is a highly prevalent opportunistic infection 












PART A Research Protocol 
 “A review of liver pathology and a clinicopathological correlation in HIV positive 
patients in Cape Town” 
1. Outline of the study population 
A database will be established of all adult HIV positive patients presenting with liver disease 
who have undergone and will undergo a liver biopsy.  The Liver Clinic and Division of 
Hepatology serves as a referral centre for patients with liver disease.  Referrals come from 
related secondary/district hospital both regionally but also supra-regionally e.g. from 
adjacent Provinces.   Part of the evaluation and management of these patients may include 
the possibility of a liver biopsy.  The study is not designed to automatically biopsy every 
patient, but rather the indications for a liver biopsy will be varied and entirely clinically 
guided.  Typically there may be several indications but common indications can be 
summarised as: 
i. An abnormal liver profile 
ii. Unexplained hepatomegaly (as defined clinically by the treating physician or as determined 
radiologically)  
iii. For pyrexia of uncertain aetiology (no cause determined despite an adequate workup).     
Initially all patients biopsied from January 2000 will be retrospectively added, thereafter all 
new patients biopsied will be included prospectively.  Hence, the database was initially 
populated with patients retrospectively and thereafter patients were prospectively included.   
All patients included retrospectively will have their biopsies accessed from the archive and 
reviewed by an experienced liver histopathologist.  They will only be included if they fulfil the 












2. Patient evaluation 
i. The HIV positive status of patients will have been confirmed with ELISA based testing for 
HIV antibody and p24 antigen.   
ii. Liver enzyme profile including total and conjugated bilirubin, alanine and aspartate 
aminotransferase (ALT, AST), alkaline phosphatise (ALP) and gamma-glutamyl 
transpeptidase (GGT) recorded at or 1 day before liver biopsy. 
iii. The CD4 positive T-cells (cells/mm3) count obtained within 4 weeks of liver biopsy. 
iv. Serological and virological markers (or previous results) for hepatitis A (Hepatitis A IgM 
antibody), hepatitis B (HBsAg, HB core IgM antibody, HBcore IgG antibody, HBeAg, anti-
HBe antibody) and hepatitis C (Hepatitis C IgG antibody) available on all patients.  HBV 
DNA viral levels and Hepatitis C genotype and viral load performed where appropriate.  
v. Liver biopsies are performed via the standard technique and use the Quick-Core® Biopsy 
Needle Set when the biopsies are performed by the Division of Radiology (under ultrasound 
guidance).  Alternatively ward based biopsies are performed using the modified Menghini 
needle, the Hepafix® 88mm biopsy needle.   As is our practice, an approximately 1mm 
piece of the core of liver tissue from every biopsy is submitted for mycobacterial and fungal 
culture in sterile 0.9% normal saline and confirmation of culture results are followed up from 
the microbiology laboratories.  Biopsy specimens are placed in formalin for histology 
processing.  
vi. All relevant patient clinical and demographic data will be recorded including age, gender, 
history of opportunistic infections including tuberculosis and mode of TB diagnosis, WHO 
clinical HIV/AIDS staging, complete drug or toxin exposure history and alcohol history.  The 














3. Histopathological examination 
i. The liver biopsy will be deemed adequate if: at least ≥1.5cm in length and/or 6 portal tracts 
are present. 
ii. Each biopsy specimen will be processed according to a standard protocol with haematoxylin 
and eosin-staining as well as utilizing Bile sirius red, reticulin, periodic acid-Schiff (PAS), 
PAS diastase and Perl’s Prussian blue stain, routinely for evaluation.  Where necessary, 
Ziehl-Neelsen stain is utilized to assess for acid-fast bacilli, Grocott’s methenamine silver 
stain for fungal organisms, and immunohistochemistry stains for hepatitis B surface and 
core antigen.  
iii. All the liver biopsies in this study are assessed by one of either two experienced liver 
histopathologists. 
iv. Clinicopathological assessments are done concurrently with 3 hepatologists.   
v. The most likely clinicopathological diagnosis(es) will be captured in the database. 
Suspected drug induced liver injuries will be based on the clinical presentation, exclusion of 
other aetiological factors and a suggestive histological pattern of injury.  The most likely 
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HIV and liver disease covers a vast area of available literature.  Even though HIV is 
a relatively “young” disease, it has generated an almost exponential rise in research.  
The major focus of this dissertation is to analyse the liver pathology observed in 
patients with HIV/AIDS in our clinical experience; our setting being a country with the 
highest prevalence of HIV globally.  Having determined this spectrum, a clinic-
pathological analysis will endeavour to identify major factors determining 
pathologies.  The foundation of this literature review is the basic immunological 
processes between HIV and the various cellular components of the liver. Building on 
this foundation is the specific objectives of this review viz. to evaluate the current 
body of data pertaining particularly to liver pathology in HIV/AIDS.  Having 
determined the scope, attention will be given to specific common pathologies to 
expand upon particular aspects of these pathologies and their natural clinical 
histories.     
 
Pubmed (MEDLINE) was utilized for the literature search. Search terms included 
“Liver pathology and HIV” in combination with “liver disease”, “viral hepatitis B and 
C”, “granulomatous inflammation” and “steatosis/steatohepatitis”. Additional 
publications were identified from the relevant literature. Publications from the last 13 
















2. The HIV/AIDS epidemic and the burden of disease 
At the end of 2011, 34 million people globally were living with HIV.  An estimated 
0.8% of adults aged 15-49 years worldwide are HIV positive.  Sub-Saharan Africa is 
the most severely affected region accounting for 70% of HIV worldwide with almost 1 
in every 20 adults HIV infected (1).  South Africa has the highest HIV prevalence 
rates in the world.  The total number of persons living with HIV in South Africa 
increased from an estimated 4 million in 2002 to 5.26 million by 2013 (2).    
 
Approximately 10.9% of the South African population is HIV positive (3) while in 
2011, the overall HIV prevalence amongst antenatal women was 29.5% (4). The HIV 
pandemic is now demonstrating features of stabilizing in South Africa, but its impact 
on healthcare delivery and the disease burden is incalculable.  Together with 
tuberculosis, HIV forms part of the now recognized 4 major burdens of disease in 
South Africa (5).  HIV/AIDS has had a significant influence on all aspects and 
disciplines of medicine.  Clinical practice and the understanding of patho-
physiological processes have needed to be adapted to the mode of presentation of 
patients with HIV/AIDS.  Liver disease is no exception and over the last decade, 
liver-related complications have become a significant cause of morbidity and 
mortality in HIV-infected patients, most notably in the developed world (6). Little is 
known about the range of liver pathology in the developing world and in particular in 
a high HIV prevalence area such as sub-Saharan Africa. This study aims to add to 














3. Epidemiology of HIV and Liver disease 
Liver disease, including both liver-related morbidity and mortality, secondary to acute 
and chronic liver disease in addition to hepatocellular carcinoma, is emerging as a 
significant management challenge in HIV infected people, mostly reported in high 
income countries (7).  The Data Collection on Adverse Events of Anti-HIV Drugs 
(D:A:D) study investigating adverse effect of antiretroviral therapy in over 33,000 
patients noted liver related mortality as the leading cause of non-AIDS mortality in 
HIV-positive patients (7).  In the study, liver related mortality was strongly associated 
with viral hepatitis (84% of liver related deaths, 11% of total deaths), however 16% of 
liver related mortality (2.3% of total deaths) was unrelated to viral hepatitis (7).  
 
Data from the developing world or low and middle income countries regarding liver-
related mortality in patients with HIV/AIDS is very limited.  A retrospective study of 
over 6007 patients from Latin America, found 42% of total deaths were attributed to 
cirrhosis or liver failure (8). This was mostly related to co-infection with hepatitis B or 
C.  In a 2005 autopsy study f om India, 3.3% of patients had cirrhosis (9), whilst a 
more recent autopsy study from India in 236 patients with HIV/AIDS, a similar 
cirrhosis incidence of 3% was observed (10).   
An autopsy study in 86 patients with HIV/AIDS from the Eastern Cape in South 
Africa noted that 10% had liver disease, although no specific details of the liver 
disease were provided in this study(11).  A more recent autopsy study from 
Johannesburg looking at causes of death in 39 adults after initiating antiretroviral 
therapy, found tuberculosis as the leading cause of death (12).  Mortality secondary 
to liver disease accounted for 2 deaths but notably 14 patients (36%) had 












4. The liver and HIV 
4.1 Direct effects on the liver 
HIV has a significant effect upon cell mediated immunity producing both immune 
deficit and dysregulation through predominantly infecting CD4+ T-cells, 
macrophages/monocytes and dendritic cells.  What is now clear is that HIV also 
infects a wide range of non-immunological cells, including cells of the liver (13).  It is 
well established that HIV gains entry into most target cells by forming a complex 
consisting of its outer envelope glycoprotein (gp120), CD4 receptor and members of 
the chemokine co-receptor family, in particular CCR5 and CXCR4 (14).    
   
A variety of seminal studies has demonstrated the susceptibility of the liver to a wide 
variety of infectious and neoplastic conditions (15-17) as a result of HIV related 
immune compromise. However, no primary hepatic process directly related to HIV is 
observed in clinical practice (18).  This is despite Kupffer cells (the resident hepatic 
macrophages), sinusoidal and biliary epithelium all expressing CD4 receptors (19).  
In some instances, a non-specific hepatitis very similar to Epstein Barr virus related 
hepatitis, can be seen in primary HIV infection (20).  This is in sharp contrast to the 
many liver abnormalities observed in the later clinical stages of HIV/AIDS.  Of 
curiosity is that evidence to suggest CD4 receptor expression by hepatocytes is 
ambiguous.  Some studies have demonstrated CD4 expression on hepatocyte cell 
lines, whilst others are CD4 negative (21, 22). Notably, chemokine co-receptor 
CXCR-4, CCR3 and CCR5 have been demonstrated on hepatocytes (23).  HIV is 
however capable of infecting several CD4 negative cell types such as fibroblasts, 
neural cells and renal tubular cells (24) suggesting CD4 independent mechanisms of 












hepatocytes (25).  What is now known is that HIV via gp120 protein signalling can 
induce hepatocyte apoptosis through the CXCR4 chemokine co-receptor in the 
absence of direct HIV infection of hepatocytes (26).  Interestingly, this effect is 
augmented in the presence of the hepatitis C E2 protein (22).  An additional effect of 
hepatocyte apoptosis is that it can trigger pro-fibrotic activity of hepatic stellate cells, 
as has been demonstrated in both HIV-HBV as well as HIV-HCV co-infection (27, 
28).  
 
Kupffer cells are a target for HIV and immunohistochemical evidence of the presence 
of HIV proteins confirm this finding (29).  Kupffer cells harbour HIV proviral DNA and 
can support in vitro HIV replication (30).  Furthermore Kupffer cell densities 
correlates with the degree of HIV related immunosuppression and may increase after 
antiretroviral therapy (31).  This decreased density may play a critical role in 
enhanced microbial translocation with consequent systemic immune activation with 
advancing HIV/AIDS (31).  
 
Limited data exists of the effect of HIV upon the lipid storing and fibrogenic hepatic 
stellate cells as well as the hepatic sinusoidal epithelium, suffice to say that both cell 
types are permissive to HIV entry (13).  Hepatic stellate cells express the chemokine 
co-receptors CCR5 and CXCR4, however this appears to be CD4 independent  (32).  
There is also data to suggest a pro-inflammatory and pro-fibrogenic influence of HIV 
on stellate cells  (33). This may play a role in enhancing hepatic inflammation and 
fibrosis in patients with acute or chronic liver injury.  HIV infected hepatic stellate 
cells demonstrate increased activation and fibrogenesis as measured by the 












monocyte chemotactic protein-1 (32).  This may well explain the accelerated 
progression to advanced fibrosis and cirrhosis observed in HIV-HCV co-infected 
patients (34).  
 
4.2 Indirect effects on the liver 
HIV infection of the gastrointestinal associated lymphoid tissue, in particular the 
CD4+ T-cells, has an effect on gut permeability.  It enhances translocation of 
bacterial endotoxins such as lipopolysaccharide or LPS.  The consequence of this is 
increased circulating levels of LPS that are thought to activate monocytes and 
contribute to chronic immune activation in HIV-infected patients (35).  LPS, via toll 
like receptor 4 (TLR-4), can activate Kupffer cells through a host of pro-inflammatory 
cytokines as well as hepatic stellate cell activation to produce monocyte chemotactic 
proteins such as CCL-2 (36).  The net result of this LPS driven cytokine and 
chemokine activation is an induction of chemotaxis of both T-lymphocytes and 






















5. Pathology of HIV-associated liver disease 
5.1      Liver enzyme abnormalities in patients with HIV/AIDS 
Liver enzyme abnormalities are commonly encountered in HIV/AIDS and are 
reported in the literature to occur in 20 – 93% of HIV infected populations (37). An 
important question is what is “normal” in the context of liver enzymes? By evaluating 
local “normal” populations laboratories typically derive values for normal ranges and 
then determine reference ranges.  However it has been suggested, for example, that 
the upper limit of normal (ULN) for alanine transaminase (ALT) levels should be 30 
U/L for men and 19 U/L for women (38).  This corresponds to the 95th percentile of 
ALT levels in a cohort of nearly 4000 first-time blood donors at low risk for liver 
disease.  Another issue is that liver enzymes are oft n mildly abnormal in the HIV 
population creating another difficulty in defining what is a “normal” baseline (39).  
The range of liver enzyme abnormalities is wide and aetiologies vary between 
populations in the developed and developing worlds in addition to differences in the 
pre-HAART and HAART era. In a Boston based study, 308 HIV positive patients 
attending a municipal clinic, one-third with CD4 counts less than 200, were evaluated 
over a 2 year period from 1990 – 1991.  In this group, 75 % had abnormal liver 
function tests, 20% regarded as severe (40).  In an Indian Public Hospital, 63% of 
HIV/AIDS patients with CD4 less than 200, had elevated liver enzymes (41).  In a 
Johannesburg based study at a large Academic hospital, 93% of those evaluated, 
had abnormal liver function tests (37),  whilst 87.6% of patients in a Nigerian tertiary 
hospital had abnormalities of their liver chemistry profiles (42).  In a more recent 
study in the USA, excluding hepatitis B and C co-infected patients in a cohort of HIV 












respectively (43).  Most elevations however were mild to moderate.  In the large 
Swiss-HIV cohort study, 16% had a chronic elevation in liver enzymes (44).  A 
Mexican study found abnormal alkaline phosphatase and alanine transferase in 45% 
of a cohort of 161 patients with HIV/AIDS (45). 
 
5.2 Liver pathology in HIV/AIDS 
Several biopsy and autopsy studies are published that describes liver pathology in 
patients with HIV/AIDS.  It is evident from this data that differences in findings are 
accounted for by the geographical source of the data viz. the developed or 
developing world as well as the presence or absence of highly active antiretroviral 
therapy (HAART).  
 
The seminal paper on the pathology observed in liver biopsies performed in patients 
with HIV/AIDS was published from a New York in 1985 (46).   Here 29 biopsies done 
in 25 patients were reviewed.  The most common histological finding was of 
macrovesicular steatosis in 55% of cases.  One third had non-caseating granulomata 
secondary to Mycobacterium avium complex and a single case due to 
histoplasmosis.  The first study from a developing country noting liver pathology was 
a 1987 Brazilian autopsy series of 12 patients with HIV/AIDS.  It revealed mostly 
opportunistic infections (Cryptococcus neoformans and Mycobacterium tuberculosis) 
as well as Kaposi’s sarcoma (47).  The same year another biopsy (29 biopsies) and 
autopsy (59 autopsies) series from the USA was published (15).  Steatosis, non-
specific portal tract inflammation and granulomata accounted for the majority of 












granulomatous change was due to Mycobacterium avium complex.  Cytomegalovirus 
hepatitis as well as lymphoma accounted for other significant findings.   
 
The largest liver biopsy series to date, published in 1996, involved a retrospective 
review of liver biopsy findings in 501 HIV patients from the New York area (48).  
Sixty-two percent of the patients had CD4 counts <100/mm3.   Granulomatous 
hepatitis was the most prevalent finding in 37.2% of patients.  In 50% of cases, it 
was accounted for by Mycobacterium avium complex and in only 7% was it due to 
Mycobacterium tuberculosis.  Viral hepatitis was seen in 18.2% of patients with 
normal or non-specific findings in almost one-third of patients.  
 
The only purely biopsy based pathological study to emerge from a high HIV 
prevalence country in the developing world is a 1999 Thailand study that evaluated 
biopsies from 46 patients (49).  Again granulomatous inflammation accounted for the 
majority finding in 50% of patients.  Granulomata were mostly non-caseating and in 
two-thirds were confirmed due to Mycobacterium tuberculosis based on culture.  Of 
the remaining third, 75% had acid fast bacilli found elsewhere and responded to the 
anti-tuberculosis therapy.  Other pathological findings included opportunistic 
infections such as histoplasmosis and cryptococcosis (13%, each) and penicillinosis 
(8.7%).  Other important findings included steatosis (4.4%), viral hepatitis (4.4%) and 
importantly drug induced liver injury (2.2%).   
 
A 2004 autopsy (155 patients) and biopsy (16 patients) from India reported non-
caseating granulomatous inflammation in 41% of cases, invariably due to 












positive patients again highlighted the common finding of granulomata on liver 
histology in 31.6% of cases (9).  Interestingly in this study most were caseating type 
epitheloid granulomata, again mostly due to tuberculosis.  Steatosis (10%) and viral 
hepatitis B (2.6%) and C (10%) accounted for other major findings. CD4 cell counts 
were not reported in these studies.  
 
A Mexican study looked at hepatobiliary diseases in 161 patients with HIV/AIDS 
treated with HAART.  Liver biopsies were performed in 85 (51%) patients.  The 
frequency of findings was granulomatous hepatitis (29%), steatosis plus 
granulomatous hepatitis (19.5%) and steatosis alone (14.6%). Opportunistic 
infections were isolated in 27.9%, Mycobacterium tuberculosis (26.6%) being the 
most frequent, Histoplasma capsulatum (20%), Cytomegalovirus (13.3%), and 
Mycobacterium avium intracellulare (11%). The HBsAg was positive in 21 of the 69 
patients (30.4%) (45).  
 
In Africa, only one liver biopsy based pathology study in HIV/AIDS patients has been 
reported (51).  Several autopsy studies have been reported although none of them 
concentrate specifically on liver disease.  In 2008, a series of 12 liver biopsies was 
reported from Nairobi, Kenya (51) with 7 of the 12 biopsies demonstrating acid fast 
bacilli positive granulomatous hepatitis.  A Nigerian study in 100 patients with 
HIV/AIDS who underwent post-mortem evaluation of the liver was reported in 2006 
(52).   Tuberculous granulomatous hepatitis (34%), chronic hepatitis (20%), non-
specific reactive hepatitis (15%) and steatosis (12%) were the most frequent 
findings. An autopsy study in 86 patients from the Eastern Cape, South Africa found 












liver pathology observed (11).  A 2012 autopsy study of 39 adults from 
Johannesburg looking at post mortem causes of death after initiating antiretroviral 
therapy (12) found that granulomatous inflammation secondary to tuberculosis was 
the most frequent liver pathology in addition to drug induced liver injuries.  
 
5.3 Specific pathology of the liver in HIV/AIDS 
5.3.1. Granulomatous inflammation 
Granulomas are focal collections of modified macrophages often coalescing to form 
multinucleate giant cells.  Occasionally they may be surrounded by a rim of 
lymphocytes and fibroblasts (53).  Granulomas can occur in the liver as a result of a 
wide variety of disorders.  Occasionally it may be due to a primary liver process but 
mostly it is secondary to a generalised systemic process.  Given the extensive likely 
aetiologies of granulomata, geographical location as well as a given patient 
population tends to determine the most likely cause (54).  Inter alia, these include 
infectious agents, immunological diseases (PBC, PSC etc), neoplasms and drugs. 
As has been indicated, the histological finding of granulomatous inflammation in liver 
pathology from patients with HIV/AIDS is the common finding in both autopsy and 
liver biopsy studies, ranging from 31 – 50% (48, 49).  Opportunistic infections 
account for the vast majority of this finding, however there is a clear difference 
between the infectious aetiology in the developed and developing world.  
Mycobacterium avium complex (MAC) and fungal infections are the dominant 
aetiologies in the developed world whilst Mycobactrium tuberculosis dominates as 
the aetiology in the developing world (55). Mycobacterium avium complex appears to 












almost non-existent in parts of Africa (56).  There is no clear reason to explain this 
observation in geographical variation.  It may well be related to the overwhelming 
burden and incidence of Mycobacterium tuberculosis in the developing world that 
virtually eclipses MAC as an opportunistic infection.  
5.3.1.1 TB immune reconstitution inflammatory syndrome (TB IRIS) 
HIV results in a progressive depletion of CD4+ T cells (57).   Tuberculosis related 
granulomas as well as lymph nodes are depleted of T-cells and contain significant 
neutrophils as well as necrosis (58).  Following the introduction of combination 
antiretroviral therapy (cART), HIV replication is rapidly suppressed.  A prompt 
increase in naïve and memory T-cells is observed (59).  Despite T-cell function in 
HIV-TB co-infected patients not being equal to that of TB non HIV infected 
individuals, the improvement in cell-mediated immunity is associated with a reduction 
in the clinical rate of TB (60).  Paradoxically, the incidence of TB increases during 
the first 3 months of cART before declining (61).   
 
In most cases this is due to an immune restoration syndrome as a result of an 
immune response against subclinical Mycobacterium tuberculosis infection.  TB IRIS 
is observed  
in HIV-infected patients as either an unmasking of undiagnosed TB or a ‘paradoxical’ 
worsening of currently treated TB affecting 20-25% of HIV patients in the first 3 
months after cART is commenced (61).  Evidence suggests that a high 
mycobacterial load is a major determinant of a pathological immune response (61).  
Hence, TB-IRIS tends to occur more frequently in patients with disseminated 
(extrapulmonary) TB, a shorter latency period of TB therapy before cART is started 












mycobacterial load.  TB-IRIS is characterized by a pronounced and atypical 
inflammatory response and severe CD4+ T-cell deficiency (invariably <50/mm3) is a 
potent predictor of TB-IRIS (66). The pathological immunological response is not 
entirely clear but an exaggerated Th1 response seems central to the process. It is 
not clear why Th1 responses are higher in patients with TB-IRIS and a deficiency of 
Treg cells (FoxP3+CD4+ cells) in patients with TB-IRIS has not been demonstrated.  
In summary available data suggests that TB related Th1 responses are increased in 
all HIV-infected patients with treated TB following cART and that the responses are 
higher in patients who develop TB-IRIS (67).   
 
Very limited data of TB-IRIS in the liver exists, suffice to say that it poses a 
significant clinical challenge given the possible likely aetiologies in a given patient 
who develops liver dysfunction after cART initiation (68).  In a previous series of 
patients with TB-IRIS, 21% had hepatic involvement with hepatomegaly and 
abnormalities of liver enzymes, predominantly involving the canalicular liver enzymes 
(69).   
 
5.3.2 Drug induced liver injuries 
A drug induced liver injury (DILI) or hepatotoxicity is essentially a diagnosis of 
exclusion when in the clinical context of abnormal liver enzyme elevations, other 
causes such as viral hepatitis, alcohol or drug abuse, immune reconstitution 
syndrome or biliary tract disorders are not found.  Although ALT is a significant 
marker of liver injury, it is neither sufficiently sensitive or specific to define or 
categorize hepatotoxicity given that it is present in tissues other than the liver (70).   












measure the fold-changes from baseline of the transaminases.  The score is graded 
as follows: grade 1 (1.25–2.5 × ULN); grade 2 (2.6–5 × ULN); grade 3 (5.1–10 × 
ULN) and; grade 4 (>10 × ULN). Hence they defined severe hepatotoxicity as grade 
3 or 4 change in aspartate transaminase (AST) or ALT levels following drug 
exposure (39).  It is however important to note that this system is primarily focused 
on hepatocellular injuries.  Cholestatic injuries, including severe injuries such as the 
vanishing bile duct syndrome, would not be accounted for with this system.  
The US Food and Drug Administration (FDA) suggests that the most critical 
evaluation of potential for severe hepatotoxicity is so-called “Hy’s Law,” derived from 
Hy Zimmerman’s observation that patients with ALT/AST elevations with 
concomitant jaundice had a poor prognosis (71).   In essence 3 basic criteria are 
utilized to define hepatotoxicity of a predominantly hepatocellular nature. These 
include (1) ALT or AST >3× ULN; (2) Total bilirubin >2× ULN and (3) no other cause 
for the enzyme elevations (72).   
The question as to whether drug induced liver injuries occur at a greater frequency in 
HIV positive patients than they do in HIV negative patients, is unclear.   A study in 
the early 1990’s showed that the frequency of drug allergy or hypersensitivity in 
patients infected with HIV ranged from 3% to 20% (73).  Another study documented 
that drug-related rashes were 100 times more common in HIV-infected patients than 
controls (74).  Consequently, similar observations have been made with regard to 
various antiretroviral drugs and other medications e.g. antituberculous drugs, 
cotrimoxazole; in HIV-infected populations. These adverse drug reactions range from 
simple limited cutaneous rashes to more complicated systemic symptoms e.g. 












Stevens-Johnson syndrome, Toxic Epidermal necrolysis and drug induced liver 
injuries.  
 
Cotrimoxazole, a commonly used antimicrobial for both prophylaxis and treatment in 
HIV/AIDS is associated with hypersensitivity reactions in 3% to 5% of HIV-negative 
patients (75).  However the prevalence of cotrimoxazole associated adverse 
reactions is significantly higher in the HIV-positive population with one report noting 
that in HIV-positive patients treated with cotrimoxazole who experienced adverse 
effects; rash occurred in 33% (76-78).  
 
An elegant 2008 study suggested that the impairment of HIV-infected cells to deal 
with reactive drug metabolites may be a putative mechanism for the increased rates 
of adverse drug reactions seen in HIV/AIDS.   The study looked at the toxicity of 
sulfamethoxazole (one half of cotrimoxazole) and its reactive hydroxylamine 
intermediate in lymphocytes transfected with the HIV tat gene.  There was a 
significant concentration-dependent increase in cell death in transfected cell lines 
expressing Tat protein compared to controls.  T cells transfected with a dose 
dependent inducible tat gene showed increased toxicity in response to 
sulfamethoxazole and its intermediate as more Tat expression was induced. It is 
thus suggested that HIV tat protein expression may increase oxidative stress within 
HIV-infected cells (79).  This could explain the increased risk of hypersensitivity 
reactions seen in cotrimoxazole use in HIV/AIDS.   
 
Given the high rates of co-infection in subsets of HIV positive populations, another 












that co- infection with hepatitis B or C possibly contributes to increased risk.   In a 
study of 134 consecutive patients receiving antituberculous drugs, the relative risk of 
developing a TB DILI if the patient had hepatitis C or HIV was elevated 5-fold and 4-
fold, respectively.  If a patient was co-infected with both, the relative risk was 
increased 14.4-fold (80).  An interesting aspect of this study was that in a few 
patients treated for hepatitis C with alpha-interferon, anti-TB drugs were successfully 
re-challenged without DILI recurrence (80).  In several studies, predictive factors for 
cART related hepatotoxicity were evaluated.  Rates of toxicity ranged from 2 to 
23.6%.  Apart from the type of antiretroviral drug used e.g. nevirapine, ritonavir, 
hepatitis C then B, were the most consistent additional factors predicting for risk (81-
84).  In a South African based cART study, rates of hepatotoxicity after commencing 
cART was 7.7 episodes per 100 person years.  The presence of HBsAg increased 
the risk of hepatotoxicity 3 fold (85).  In a study of 400 HIV positive patients, of whom 
15% were hepatitis C and 8% were hepatitis B co-infected, viral hepatitis remained 
associated with an increased risk of hepatotoxicity with relative risks of 2.78 (95% CI, 
1.50–5.16) and 2.46 (95% CI, 1.43–4.24) for HBV and HCV infection, respectively 
(86). The risk of a DILI with nevirapine use, particularly in pregnancy, is notably 
elevated in the presence of hepatitis C co-infection.  This was the observation from 
the ATHENA cohort where 425 pregnant and 1121 non-pregnant women were 
evaluated.  Here, independent risk factors of hepatotoxicity in all women were the 
presence of detectable HCV RNA (OR 5.48, 95% CI 2.25-13.38, p<0.001) and 
nevirapine use (OR 2.63, 95% CI 1.54-4.55, p<0.001).   However, stratified for 
pregnancy, the adjusted risk of hepatotoxicity was significantly associated with HCV 













HIV increases the risk of tuberculosis 6 - 50 fold. (88).  In the treatment of TB, one of 
the most frequent adverse events in patients is liver toxicity (89, 90).   Up to 20% of 
patients develop asymptomatic elevation of liver enzymes (as a result of adaptation) 
which is usually self-limiting in most  (91).  In those who develop jaundice, ascites, 
encephalopathy or acute liver failure, the outcome is far less favourable (92, 93).  
Antituberculous DILI encompasses a wide spectrum of liver injury ranging from 
asymptomatic minimal elevation of liver enzymes to acute liver failure, often leading 
to death.  Unlike paracetamol and other non-TB antimicrobials in high income 
countries, TB drugs are a leading cause of acute DILI leading to death in low and 
middle income countries (93, 94).  
 
In a single centre registry of 303 patients in Bangalore in India, TB drugs contributed 
to 58% cases of DILI whilst in another series looking at acute liver failure in New 
Delhi in India, TB drugs contributed to 5.7% patients with acute liver failure carrying 
a 67% mortality (92, 94).  An area of limited data is that although the risk factors for 
liver toxicity during TB treatment have been assessed in HIV-negative patients, there 
is limited data in HIV/AIDS patients. What is accepted is that HIV-infection increases 
the risk of hepatotoxicity during standard multidrug treatment of active TB (80, 90, 
95).  The reasons as to why HIV-TB co-infected patients have an increased risk of 
TB DILI are unclear.  HIV/AIDS patients with acute illnesses have altered activities of 
oxidative pathways, which may partly explain their increased risk of TB DILI (96).   
The additional use of cART amplifies potential risks of toxicities and the concomitant 
use of fluconazole, which is often used in HIV/AIDS patients, is also a risk factor for 













Liver enzyme elevations following the initiation of highly active antiretroviral therapy 
has been a frequently observed complication of HIV treatment with grade 3 and 4 
hepatotoxicity observed in 8.5 – 23% of patients (39, 44, 98, 99).  In longstanding 
exposure to cART, cholestatic changes in liver enzymes seem to predominate (100).  
More recently approved antiretroviral drugs demonstrate a better hepatic safety 
profile with risks of grade 3 to 4 hepatic toxicity less than 3% (101).  Severe DILI can 
present as acute liver failure and in a retrospective analysis of 16 studies in the US 
AIDS Clinical Trials Group, 8851 patients were studied to assess risk factors for 
developing severe hepatotoxicity (102).    Early (0 – 6 months) and late (7 – 12 
months) severe hepatotoxicity was associated with abnormal baseline liver function 
test results and didanosine containing cART.  Elevated creatinine (>1.5 X upper limit 
of normal) and low platelet count (<75 X 109) were also noted as risk factors 
although these variables might have been indicative of unrecognised chronic liver 
disease and portal hypertension (103).  An additional factor noted was the presence 
and degree of fibrosis given that in a prospective study of 107 patients co-infected 
with HIV and HCV, hepatotoxicity events were higher in advanced fibrosis (Metavir 
F3 or F4) than in mild fibrosis (38% vs 15%) (104).  A 12-fold increase in nevirapine 
hepatotoxicity has been reported in female patients with CD4 cell counts of greater 
than 250/mm3 (105, 106).   Although mechanisms of hepatotoxicity of protease 
inhibitors are not clearly understood, 1.9 - 5% of patients on protease inhibitors 
experience hepatotoxicity (107).  
 
Five patterns of liver injury can occur with cART: hypersensitivity/immunoallergic, 
idiosyncratic reactions, mitochondrial toxicity, immune reconstitution syndrome and 












and are in essence very similar to DRESS syndrome (drug reaction, eosinophilia, 
and systemic symptoms).  It usually starts within 7 - 14 days of starting offending 
drug although delayed presentation at 6–12 weeks has been reported (106, 108). 
Hypersensitivity reactions are reported to occur with nevirapine, abacavir and 
efavirenz.  There is no dose relation and symptoms generally resolve after stopping 
the drug although systemic steroids may be required.  Nucleoside reverse 
transcriptase inhibitors (NRTIs) cause mitochondrial DNA depletion through their 
effect on mitochondrial gamma-polymerase.  This results in impaired fatty acid 
oxidation, microvesicular steatosis and occasionally lactic acidosis.  The risks of 
toxicity are greatest with didanosine and stavudine (109).  Mitochondrial toxicity 
usually occurs weeks to months after starting cART and is associated with elevated 
ALT/AST, lactate, amylase, and lactate dehydrogenase (LDH).  Insulin resistance 
secondary to longstanding cART, notably the NRTIs, contributes to the development 




















5.3.3 Viral hepatitis 
5.3.3.1 Hepatitis B  
Hepatitis B virus (HBV) is the most common cause of chronic liver disease 
worldwide, with over 400 million people chronically infected (111).  HBV is endemic 
in sub-Saharan Africa, with prevalence rates for hepatitis B surface antigen (HBsAg) 
positivity ranging from 5–20% (112).  Furthermore, up to 80% of HBsAg negative 
individuals in a West Africa study have circulating antibodies against hepatitis B core 
antigen immunoglobulin G (HBc-IgG), which confirms previous exposure to HBV 
(113).  
 
Approximately 5 – 10% of HIV positive patients worldwide are co-infected with HBV 
(114).  Given the HIV pandemic in sub-Saharan Africa, there are probably a large 
number of HIV/HBV-co-infected people.  The prevalence of HBV infection varies by 
risk factor and geographic region and is influenced primarily by the age at which 
infection predominantly occurs (114).  The endemicity of infection is high in parts of 
the world where infections predominantly occur during childhood or in the perinatal 
period e.g. South-East Asia, Sub-Saharan Africa, whilst it is intermediate in areas of 
mixed pattern acquisition i.e. infanthood, childhood and adulthood e.g. Eastern 
Europe, Russia, Middle East. It is low in other parts of the world (typically high 
income countries) and immigration from high endemic areas to low prevalence areas 
accounts for recent increases (115).  Co-infection rates in South Africa have been 
reported to occur between 5 – 20% (85, 116, 117).  
 
Given that HIV suppresses the immune system, it intuitively seems that HBV would 












from HIV may not accelerate liver disease progression since HBV-related liver 
disease is primarily immune mediated.  However, pathology studies in the literature 
are few but conflicting.  One of the earliest studies in 1986 looked at liver biopsies in 
54 co-infected men.  It was noted that liver injury was milder than anticipated despite 
high levels of viraemia and thought to be due to patients being less immunologically 
responsive to hepatitis B virus  (118).  A second study comparing 20 HIV positive co-
infected patients with HIV negative controls similarly found lower histological activity 
indices in the presence of high levels of HBV replication.  Fibrosis scores were also 
lower (119).  A later study of 132 patients was the first to demonstrate that whilst 
necro-inflammatory activity was not necessarily elevated the degree of fibrosis and 
risk for cirrhosis was clearly elevated (120).  Another study came to similar 
conclusions however in this series of 260 patients; necro-inflammatory activity and 
fibrosis were enhanced in HIV-HBV co-infected patients (121).  Importantly the first 
case of fibrosing cholestatic hepatitis in a co-infected patient was described in 1993 
(122).  Fibrosing cholestatic hepatitis is an intriguing condition occurring in 
immunosuppressed individuals with hepatitis B virus infection, unfortunately carrying 
a poor prognosis.   Exuberant viral replication produces progressive jaundice and 
fibrosis in the absence of significant necro-inflammation.  
 
There are several natural history studies that have shed light on the balance 
between the opposing forces of HIV and HBV.   As a result of the important role 
played by the host immune response in control and clearance of HBV, HIV has 
significant impact on the course of disease. To consider co-infection, it is necessary 
to view the effect of HBV on HIV and vice versa.  Firstly, it is generally accepted that 












affects the progression of HIV have produced conflicting results.  Studies from the 
pre-HAART era did not demonstrate a significant impact of HBV on HIV progression 
and data from the large EuroSIDA cohort found that HBsAg positivity did not affect 
the incidence of new AIDS defining events.  Furthermore even with adjusting for 
confounding variables e.g. use of cART, baseline viral loads, CD4, age and ethnicity, 
the time taken for patients to reach undetectable HIV viral loads after 6 to 12 months 
on cART, was not affected (123, 124).  There is however one recent study that 
suggests that HBV infection might indeed have a deleterious effect on HIV 
suppression.  Patients infected with HIV and HBV who started cART had a 
significant rebound of HBV DNA after interruption of cART, along with accelerated 
immune deterioration (decrease in CD4+ cell count) (125). 
 
The natural history of HBV is modified by HIV.  There is an elevated risk of chronic 
HBV infection after acute infection in HIV positive adults (23% in HIV+ versus 4% in 
HIV -) (126, 127).   HBV relapse (so-called sero-reversion) and the re-emergence of 
HBsAg, HBeAg or HBV DNA together with clinically significant disease can occur 
(114, 126)   In those with chronic HBV infection, the risk of liver-related morbidity and 
mortality substantially increased in persons with HIV infection compared to those 
with HBV alone.  In a long-term cohort study of 5923 men, liver related mortality rate 
was higher in men with HIV and HBsAg (14.2/1000) than in those with only HIV-1 
infection (1.7/1000, P < 0.001) or only HBsAg (0.8/ 1000, P < 0.001) (128).  After 
initiating cART, the effect of antiretroviral-related immune restoration has been 
associated with spontaneous recovery from chronic HBV infection but, in other 
studies, with flares of hepatitis B. Immune reconstitution hepatitis seems to occur 












Several studies have found that HBsAg-positive patients with a low CD4+ cell count 
nadir face an increased risk of liver-related death (128, 130).  Data derived from HIV-
negative persons suggest that higher levels of HBV DNA (≥4 log10 copies/mL) may 
be associated with an increased risk of cirrhosis and hepatocellular carcinoma; 
however, the relation between HBV DNA level and clinical outcomes has not been 
adequately studied in co-infected persons.  (131, 132).   Effective anti-HBV 
containing cART has beneficial effects on the clinical course of HBV.  Lamivudine 
containing ART was associated with decreased risk of liver-related death in >2000 
HBV/HIV co-infected persons (133).  There are other data to suggest that 
antiretroviral regimens that contain drugs active against HBV infection (e.g., 
tenofovir, emtricitabine, and lamivudine) modifies the natural history of HBV disease 
in HIV-infected persons by slowing disease progression and, in some patients, 
leading to seroconversion.  Use of dual agents active against HBV dramatically 
reduces the emergence of resistance; however, long-term follow-up is still needed to 
evaluate the natural history.   The earlier use of HAART (CD4 ≤500) with dual activity 
to ameliorate HBV liver disease progression before severe immunocompromise 
occurs is recommended (134).   Current thinking therefore holds that early use of 
HAART containing dual-activity agents is generally positive for preventing severe 
immune dysfunction, controlling HBV replication, slowing liver disease progression, 
















5.3.3.2 Hepatitis C  
Approximately 180 million people worldwide are chronically infected with hepatitis C 
virus (135).  With decreasing mortality from AIDS-related opportunistic infections with 
the advent of HAART, liver disease has emerged as a very important cause for 
morbidity and mortality in the HIV-HCV co-infected population (136).   As HIV related 
mortality has declined, hepatitis C related liver disease has become a leading cause 
of hospitalization and death in the co-infected population. Overall, HIV infection has 
a detrimental effect on the natural history of HCV disease; HIV-infected patients are 
less likely to clear hepatitis C following acute infection, have higher HCV RNA loads, 
and experience more rapid progression to end stage liver disease than those without 
HIV.(137, 138).   
 
Approximately 30% of patients infected with HIV in the USA and Europe are also 
infected with hepatitis C (139).   The high prevalence of HIV-HCV co-infection is not 
unexpected because both viruses are transmitted by the same routes, although not 
with the same efficiency.  As a result, the prevalence of HIV-HCV co-infection varies 
across subpopulations of HIV-infected patients. For example, people acquiring HIV 
through exposure to contaminated blood (such as injecting drug users or 
haemophiliacs) are more likely to have HCV co-infection than those acquiring HIV 
through sexual transmission.  In populations of injecting drug users in the USA and 
Europe, up to 75% of HIV positive patients are hepatitis C co-infected (140, 141).  
The picture appears to be different in Africa where HCV co-infection rates seem to 
be much lower suggesting that modes of transmission likely differ.  Many patients 
have no identifiable risk factor and although nosocomial spread is important, the 













The presence of both HIV and HCV infection complicates the natural history of both 
viruses and their treatment (144).  HIV influences HCV and co-infected patients have 
higher HCV viral loads than patients infected with HCV alone.  HIV infection and the 
related immunosuppression produce more rapid progression of liver disease to 
cirrhosis, end-stage liver disease and death (145).  In some studies, HIV/HCV co-
infection was associated with more rapid progression to AIDS and death (145).  HCV 
infection may be associated with an increased risk of ART associated hepatotoxicity 
(146).  Since the introduction of HAART, liver-related morbidity and mortality has 
increased markedly in HIV-infected patients, particularly those co-infected with 
hepatitis C. The rate of liver-related complications increased from 5.4 to 26.7 
admissions per 100 patient-years in HIV/HCV-co-infected patients treated at a large 
urban hospital between 1995 and 2000(147).  In addition, liver disease was the 
second leading cause of death (0.23 cases per 100 person-years) after HIV/AIDS 
(0.59 cases per 100 person-years) and ahead of cardiac disease (0.14 cases per 
100person-years) among 23 441 patients enrolled in the D: A: D study (148). 
 
Hepatitis C may also have a deleterious effect on HIV, however the mechanisms by 
which HCV potentially affects HIV are unclear.  There is speculation that HIV may be 
accelerated by HCV-related immune activation with consequent impairment in 
immune recovery following HAART. In a study of 3111 Swiss patients receiving 
HAART, it was observed that co-infected patients had an increased risk of 
progression to AIDS and AIDS-related death (149).  This may reflect impaired CD4 
cell recovery in co-infected patients on HAART however since there are many 













As the life expectancy of individuals who are HIV positive improves, organ 
dysfunction associated with ageing becomes a more relevant issue.  Apart from 
chronic viral hepatitis and alcoholic liver disease, one of the major causes of hepatic 
disease in the developed world is non-alcoholic fatty liver disease (NAFLD).  NAFLD 
has been identified in up to 30% of HIV mono-infected Americans, although this 
study was unable to demonstrate whether the prevalence of NAFLD was different to 
HIV-negative individuals (150) .  NAFLD is the primary manifestation of the metabolic 
syndrome in the liver with lifestyle, in addition to low exercise and poor diet, being 
the major determinants for the risk of NAFLD.  HIV itself, probably in addition to 
insulin resistance driven by anti-retroviral drugs, in particular NRTIs, contributes to 
the higher rate and severity of NAFLD in HIV/AIDS (151, 152).  Steatohepatitis 
(simple steatosis with inflammation), may produce progressive fibrosis leading to 
cirrhosis (153).  Nearly half of HIV/AIDS patients undergoing evaluation for 
unexplained liver test abnormalities have NAFLD (153, 154).  In a French liver 
biopsy study of 30 HIV positive patients with persistently abnormal liver profiles, 18 
had steatosis with severe fibrosis in six patients (155).  It should however be noted 
that alcohol abuse remains prevalent in HIV populations and can produce a liver 
injury pattern indistinguishable from that of non-alcoholic steatohepatitis.  Alcohol 
consumption thus always needs to be accounted for.  Few studies of NAFLD have 
been published from low and middle income countries, especially Africa, however 














5.3.5 AIDS cholangiopathy 
In 1986, Margulis et al described biliary disease resembling sclerosing cholangitis 
with benign strictures in 3 patients with advanced HIV/AIDS (156).  Stenosis of the 
distal common bile duct and irregularity of the smaller intrahepatic and extrahepatic 
ducts was observed in patients with either cryptosporidium or cytomegalovirus 
infection of the biliary tree.  It was initially assessed as being due to HIV itself.   
Cholangiopathy was seen exclusively in patients with advanced HIV and CD4 cell 
counts were invariably <100 cells/mm3 (157).  The aetiology is not entirely clear, but 
several opportunistic infections (Cryptosporidium parvum, Microsporidium, 
Cytomegalovirus, Cyclospora cayetanesis, Isospora belli) are suspected to cause it.  
Elegant work in 2007 suggested that the possible pathogenic mechanism through 
which HIV infection could cause AIDS-related cholangiopathy is through HIV tat 
protein  enhancing Cryptosporidium parvum induced apoptosis of cholangiocytes via 
a Fas-ligand dependent mechanism (158).   Endoscopic retrograde 
cholangiopancreatography (ERCP) or Magnetic Resonance 
cholangiopancreatography (MRCP) is the diagnostic gold standard.  ERCP identifies 
4 particular patterns of stenosis: (1) Sclerosing cholangitis and papillary stenosis – 
50% of cases, (2) Papillary stenosis only – 15% of cases, (3) Intrahepatic sclerosing 
cholangitis only – 20% of cases and (4) Long extrahepatic bile duct strictures ± 
intrahepatic sclerosing cholangitis – 15% of cases (159).   ERCP offers a therapeutic 
means to provide symptomatic relief in cases of papillary stenosis (160).  Clinically, 
the presentation of cholangiopathy may be variable, even completely asymptomatic.  
Right upper quadrant pain and fever accompanied by an elevated serum alkaline 
phosphatase (ALP) and gamma-glutymyl transferase (GGT) are the most common 












early initiation of HAART is preventive, without HAART the median survival is 9 




The body of literature with respect to HIV/AIDS and liver disease is extensive.  What 
emerges is a clear difference in the spectrum of pathology in the pre-HAART and 
HAART era.  However superimposed on this is another layer of difference between 
the developed and developing world or more precisely high and middle or low 
income countries.  It is the latter countries that carry a disporportionately higher HIV 
burden and where the data on liver disease is most limited.  Data on clinical liver 
disease abounds from high income countries however here too pathology based 
studies are limited.   
Our study represents the largest of its kind ever performed in the developing world.  
It is primarily aimed at filling the data gap for countries with a very high burden of HIV 
and to determine the factors that characterise liver disease in this population. 
Patterns that emerge from the data will also potentially assist in guiding clinical 
practice nationally and sub-regionally.  This is of value given that access to tertiary 
investigations such as liver biopsy to guide patient management is not widely 
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Globally, approximately 34 million people are HIV infected with 70 % of those 
infected residing in sub-Saharan Africa (1).  South Africa is the epicentre of the 
pandemic with some 5.6 million people living with HIV and 10.6% of the adult 
population HIV infected (2).  The high tuberculosis (TB) prevalence compounds the 
challenge.  TB-HIV co-infection is a significant burden with up to 65% of newly 
diagnosed sputum positive TB patients being HIV positive (3).  In addition, South 
Africa, in keeping with sub-Saharan Africa, is an endemic area for hepatitis B with 5-
15% of the South African population positive for HBsAg.  Over the last decade, a 
wide scale public access programme means that almost 2 million South Africans 
currently access highly active antiretroviral therapy (HAART) (4). 
HIV-related liver disease has emerged as a significant cause of morbidity and 
mortality, both in the pre-HAART, but particularly in the HAART era of HIV/AIDS (5, 
6).   Most data in this regard has come from high income countries with the D: A: D 
study identifying liver-related mortality as the leading cause of non-AIDS mortality in 
HIV-positive patients (7, 8). Data from studies primarily assessing liver pathology in 
patients with HIV/AIDS is limited and studies were mostly performed prior to the 
availability of HAART (9-13).  Invariably, a difference exists in findings between high 
and middle or low income countries.  The largest series to date of 501 liver biopsies, 
done in the pre-HAART era in New York, reported granulomatous inflammation, 
predominantly due to Mycobacterium avium complex, and viral hepatitis as the most 
frequent pathological findings (11).   Steatosis has also been frequently reported in 
other liver biopsy series from both high and low income countries (9, 10, 13, 14).  
Similarly, limited data from low and middle income areas, has reported 
granulomatous inflammation as a prevalent pathological finding. However, in 












cause of granulomatous inflammation.   A series of 46 liver biopsies from Thailand, 
apart from MTB related granulomatous inflammation, reported viral hepatitis, 
steatosis and drug-induced liver injuries (DILI) as prevalent findings (12).    A recent 
autopsy study from South Africa in patients after the initiation of antiretroviral therapy 
reported MTB related granulomatous inflammation and DILI as notable findings (15).   
Liver enzyme elevations following the initiation of highly active antiretroviral therapy 
has been a frequently observed complication of HIV treatment, with grade 3 and 4 
hepatotoxicity observed in 8.5 – 23% of patients (16-18).  The question as to 
whether drug- induced liver injuries occur at a greater frequency in HIV positive 
patients than they do in HIV negative patients is unclear, although hypersensitivity 
reactions to drugs such as sulfamethoxazole-trimethoprim (cotrimoxazole, BactrimR) 
occur at a greater frequency in HIV positive than HIV negative individuals (19).   
Data on the histopathological spectrum in patients with HIV/AIDS presenting with 
liver disease and the clinical correlates in a high HIV prevalence middle or low 
income country is limited.  Given this, our aim was to evaluate our clinicopathological 


















Patients and Methods 
Study population 
In 2005, a database of all adult HIV positive patients with liver disease referred to our 
centre for evaluation and who consequently had a liver biopsy, was established.  
Retrospectively, patients were included from January 2000 to May 2005.  Thereafter, 
patients were prospectively enrolled until June 2013.  Indications for liver biopsy 
varied but mostly included abnormal liver profile, hepatomegaly (as defined clinically 
by the physician or radiologically) or pyrexia of uncertain aetiology (temperature 
>38oC for ≥1 week with no cause despite an adequate workup).  The ultimate 
decision to perform a biopsy was clinically based.  In patients with suspected drug 
injuries, biopsy was indicated with rising liver enzymes, incomplete resolution after 
drug withdrawal or a consideration for specific therapy e.g. corticosteroids.  The HIV 
positive status of patients was confirmed with ELISA based testing for HIV antibody 
and p24 antigen and patients were staged clinically using the World Health 
Organization clinical staging system for HIV/AIDS (20).  Liver biopsies were 
performed via the standard technique using either the Quick-Core® Biopsy Needle 
Set (Cook Medical, Bloomington, IN, USA) or using the modified Menghini Hepafix® 
88mm biopsy needle (B. Braun Melsungen AG, Melsungen, Germany).  As per our 
standard practice, approximately 1mm of the core of liver tissue from every biopsy 
was submitted for mycobacterial and fungal culture and confirmation of culture 
results obtained from the microbiology laboratories.  Autopsy based data was not 
included.   A liver biopsy was deemed adequate if ≥1.5cm in length with at least 6 
portal tracts present.  Biopsies of patients that were initially added retrospectively (64 












Town and also reviewed for adequacy of assessment and inclusion in the study.  All 
relevant clinical and demographic patient data was recorded including age, gender, 
history of opportunistic infections including tuberculosis and mode of TB diagnosis, 
WHO clinical HIV/AIDS staging, complete drug or toxin exposure history and alcohol 
history.  The study was performed in accordance with the Declaration of Helsinki and 
approved by the University Of Cape Town Faculty Of Health Sciences Research 
Ethics Committee (REC 187/2005). 
Laboratory tests 
Liver enzyme profiles including total and conjugated bilirubin, alanine and aspartate 
aminotransferase (ALT, AST), alkaline phosphatase (ALP) and gamma-glutamyl 
transpeptidase (GGT) were recorded at or 1 day before liver biopsy.  Grading of 
hepatoxicity for suspected drug injuries was done utilizing the Adult AIDS Clinical 
Trials Group definitions of hepatotoxicity (21).  The CD4 positive T-cells (cells/mm3) 
obtained within 4 weeks of liver biopsy was recorded.  HIV RNA quantification was 
not routinely recorded given that the antiretroviral treatment protocol only allows for 
testing 6 months after initiating therapy.  Serological and virological markers for 
hepatitis A (Hepatitis A IgM antibody), hepatitis B (HBsAg, HBcore IgM antibody) and 
hepatitis C (Hepatitis C IgG antibody) were obtained on all patients.  Patients who 
were HBsAg positive had additional testing for HBeAg and anti-HBe antibody.  In 
some patients negative for HBsAg, total anti-HB core antibody was tested to 
determine previous hepatitis B exposure status.  Anti-HDV was not tested in HBsAg 
positive patients given that South Africa is an HDV non-endemic area.  All 
serological testing was done using the ARCHITECT I or II system (Abbott 
Diagnostics Division, Wiesbaden, Germany).   HBV DNA viral levels were assessed 












Germany) up to 2009, when a change was made to the Cobas Ampliprep/Cobas 
Taqman HBV test, version 2.0 (Roche Diagnostics GmbH, Mannheim, Germany).    
Those positive for hepatitis C IgG antibody had subsequent hepatitis C PCR 
confirmed by means of an in-house PCR technique after amplifying the 5’NCR 
region of the virus.  Hepatitis C genotype was done using the Versant HCV 
Genotype 2.0 Assay Line Probe Assay (Siemens AG Healthcare, Munich, Germany).  
Hepatitis C viral load assessment was done by a reference laboratory utilizing the 
COBAS Ampliprep/Cobas TaqMan v2.0 (Roche Diagnostics GmbH, Mannheim, 
Germany).   
Histopathological examination 
Biopsy material was routinely haematoxylin and eosin-stained in addition to Bile 
sirius red, reticulin, periodic acid-Schiff (PAS), PAS diastase and Perl’s Prussian 
blue stain. Where necessary, Ziehl-Neelsen stain was utilized to assess for acid-fast 
bacilli, Grocott’s methenamine silver stain for fungal organisms, 
immunohistochemistry stains for hepatitis B surface and core antigen and CK7 stain 
for bile duct epithelium.  All the liver biopsies in this study were assessed by one of 
either two experienced liver histopathologists.  Clinicopathological assessments 
were done concurrently with hepatologists.  The diagnosis of a drug-induced liver 
injury was determined by the exclusion of viral hepatitis, the temporal relationship 
between drug or toxin exposure and the injury, signature biochemical patterns of 
given drugs, effect of drug de-challenge and compatible histological patterns.  Drug 
induced liver injuries were categorised into one of the following histological patterns 
of injury.  Firstly, non-specific hepatitis in which there was portal and/or lobular 
inflammation particularly in zone 3 with/without cholate stasis in zone 1, with 












which there was marked bilirubinostasis involving predominantly zone 3 and minimal 
interface or portal tract inflammation.  Thirdly, mixed hepatitic-cholestatic in which 
there was a combination of portal tract inflammation/interface hepatitis with 
inflammatory cells, including lymphocytes and eosinophils together with marked 
zone 3 bilirubinostasis and a ductular reaction.  Fourthly, sub-massive necrosis in 
which zonal or panzonal necrosis was present.  Fifthly ductopenia with a “vanishing 
bile duct syndrome” pattern with cholate stasis, bile duct targeting and absence of 
bile ducts on CK7 stain.  The sixth pattern was microvesicular steatohepatitis with 
steatosis, ballooned hepatocytes and necroinflammatory foci with or without 
Mallory’s hyaline occurring in the setting of known drug exposure and other 
aetiological factors excluded.  The seventh pattern of non-necrotizing granulomatous 
inflammation was ascribed to drugs only after an exhaustive exclusion of 
mycobacterial infection and in a few instances lack of response to a trial of anti-TB 
drug therapy.  Findings of  hepatocyte “pseudo-ground glass change” (in HBV 
negative patients) thought to be drug- related, but in the absence of any significant 
inflammatory changes, cholestasis or any typical histological pattern of drug injury, 
was termed drug adaptive or related changes and not regarded as a DILI.  
Granulomas were classified as necrotizing (caseous) or non-necrotizing (non-
caseous). By local convention and practice, histological grading and staging of 
hepatitis B utilized the criteria as proposed by Ishak et al (26), whilst hepatitis C was 


















Values are expressed as the median and interquartile range for continuous 
variables.   Clinical characteristics were summarized in the total cohort using 
standard descriptive characteristics. Differences between different qualitative 
parameters were explored using the chi-square, Fishers exact or Mann-Whitney U 
test, where appropriate. Odds ratios of a DILI relating to specific drugs were 
calculated with a 95% confidence interval.   Multiple logistic regression analysis 
utilizing the following factors: age, female gender, CD4 cell count<200, alcohol use, 
presence of HBsAg and the likely offending drugs was utilized to explore baseline 
demographic, clinical characteristics and likely offending drug associated with the 
risk of a specific histological pattern of DILI.  A P-value of <0.05 was set as the 






















Patient characteristics. Table 1 demonstrates the demographics and 
characteristics of a total of 301 HIV positive patients who underwent percutaneous 
liver biopsy and were enrolled in the cohort.  There were marginally more men than 
women, 52% vs. 48%, and patients were young with a median age of 34 years.  
Woman were significantly younger than men (P<0.001) and ethnically, the majority of 
patients were Black.  Patients had advanced HIV/AIDS with a median CD4 cell count 
of 127 (IQR 52-260).  A total of 66.7% had a CD4 cell count <200 cells/mm3 with 
23.3% <50 cells/mm3.   Correspondingly almost half of patients were clinically WHO 
stage 4.  Almost a quarter of patients consumed alcohol on a regular basis, males 
more so than females (P<0.0001).  Fifty-six patients (18.6%) were hepatitis B co-
infected with a far smaller number of patients co-infected with confirmed hepatitis C 
(3.3%).   Medication drug exposure by patients within 4 weeks of liver biopsy is as 
listed in Table 1. Polypharmacy was prevalent with 83 (27.5%), 67 (22.2%), 62 
(20.5%), 35 (11.6%) of patients using HAART/cotrimoxazole, anti-TB 
drugs/cotrimoxazole, HAART/anti-TB drugs and HAART/cotrimoxazole/anti-TB 
drugs, respectively.   HAART regimens were predominantly dual NRTI plus NNRTI 
based (Table 2), the predominant NNRTI being efavirenz.   
Clinicopathological findings. Histological findings and/or clinicopathological 
correlates are as listed in Table 3.  DILI was the predominant finding (42.2%), 
followed by granulomatous inflammation (29%), steatosis/steatohepatitis (19.3%) 
and hepatitis B (19%).  Hepatitis C was confirmed in 10 (3.3%) from 11 HCV 
antibody positive patients.   Lymphoma was diagnosed in 7 (2.3%) patients, the 












was observed 24 (8%) of patients with the majority, 19 (79%), of black ethnicity.  The 
finding of siderosis was invariably observed in conjunction with other pathology viz. 
steatohepatitis 8 (33%), steatosis 7 (29%), granulomatous inflammation 4 (17%), 
respectively.  AIDS cholangiopathy was suspected in 7 (2.3%) patients and was 
confirmed by radiological imaging (5 by MRCP and 2 with ERCP).  Drug adaptive or 
related changes occurred in 7 (2.3%) patients.  A total of 49 (16.2%) patients had 
more than 1 pathological finding on biopsy.  The majority of granulomatous 
inflammation in 79 (92%) patients was non-necrotizing. Mycobacterium tuberculosis 
accounted for the majority of granulomatous inflammation observed and was 
cultured in 61 (71%) patients – 12 (19.6%) from liver tissue, 32 (52.4%) from sputum, 
3 (4.9%) from urine and 14 (23%) from miscellaneous tissues/fluids (lymph node 
aspirates, pleural fluid, bone marrow).  In 3 (3.5%) patients, Mycobacterium avium 
complex was cultured from liver tissue and 1 (1.1%) patient demonstrated a positive 
Grocott’s methenamine silver stain for fungal elements and subsequently cultured 
Cryptococcus neoformans.  
Drug induced liver injuries. Table 4 demonstrates the liver enzyme profiles and 
grading of the various histological patterns of suspected DILI.  Drug related/adaptive 
changes are included in Table 4, but were not regarded as a DILI.  Jaundice was not 
a significant features in those with non-specific hepatitis.  The ALT and AST levels 
differed only between the non-specific hepatitis and submassive necrosis groups, 
P<0.001, whilst ALP and GGT levels differed between non-specific hepatitis, 
cholestatic, mixed cholestatic-hepatitic and ductopenic patterns of DILI, P<0.001.  
The grades of hepatoxicity based on median ALT are as listed in table 4.  Ductopenic 
injuries and submassive necrosis were grade 3 and 4, respectively.  All others were 












Univariate analysis (Table 5) suggested that age may play a factor for a DILI, 
P=0.079, however gender and CD4 cell count did not play a role.  Cotrimoxazole, 
HAART and herbal medication were most likely to be associated with a DILI.  Table 6 
demonstrates the clinical and demographic factors as well as the drugs associated 
with a specific histological DILI pattern using multivariate logistic regression analysis.  
Non-specific hepatitis was associated with cotrimoxazole (OR, 3.82; 95% confidence 
interval, (1.82-8.0); P=0.001), efavirenz (OR, 4.3; 95% confidence interval, 1.92-9.83; 
P<0.001), nevirapine (OR, 9.6 95% confidence interval, 2.25-40.86; P=0.002) and 
anti-TB drug (OR, 8.1; 95% confidence interval, 2.4-27.81; P<0.001) use with no 
other factors demonstrating an association.  Cholestatic injury was associated with 
female gender (OR, 3.25; 95% confidence interval, 1.08-9.72); P=0.03) and 
cotrimoxazole use (OR, 7.05; 95% confidence interval, 2.5-19.89; P<0.001).  Mixed 
cholestatic-hepatitic injury was primarily associated with cotrimoxazole (OR, 3.99; 
95% confidence interval, 1.57-10.17; P=0.003), whilst efavirenz demonstrated a 
trend to significance (OR, 2.69; 95% confidence interval, 0.86-11.5; P=0.07).  
Submassive necrosis was associated with younger age (OR, 0.88; 95% confidence 
interval, 0.81-0.96; P=0.003), higher CD4 cell count (OR, 0.21 95% confidence 
interval, 0.06-0.78; P=0.012) and efavirenz (OR, 10.46; 95% confidence interval, 2.7-
40.5; P<0.001). The vanishing bile duct pattern was only associated with 
cotrimoxazole (OR, 17.6; 95% confidence interval, 3.26-95.3; P<0.0001).  
Viral hepatitis. Table 7 highlights the 56 patients with hepatitis B, 32 (57%) HBeAg 
positive and 24 (43%) HBeAg negative.  Median age did not differ between the 2 
groups (P=0.49) and neither did the alanine (ALT) and aspartate (AST) 
aminotransferase levels (P=0.8, 0.5; respectively).  Despite the median CD4 cell 












(P=0.03, 0.008; respectively), median histological staging and grading, did not differ 
(P=0.2, 0.8; respectively).  Of note, 99 patients who were negative for HBsAg were 
screened for anti-HB core antibody and 66 (66.6%) were positive.  In the 10 patients 
with confirmed hepatitis C, genotype 1a was the predominant genotype,  8 (80%), 
with the remaining 2 patients being genotype 2 and 3a, respectively.  Median (range) 
METAVIR fibrosis score was 2 (1-4), with 4 patients (40%) being ≥F3.  Median 


























This study, the largest of its kind from a middle or low income country with a high 
HIV burden, demonstrates the extensive range of liver pathology observed in this 
particular setting.  The demographics of this 301 patient cohort is representative of 
the broader HIV population and epidemiology in South Africa where patients often 
present with advanced HIV/AIDS and females are invariably younger  (22).   The 
CD4 cell counts at the time of biopsy were low.  In keeping with a previously reported 
pattern, females had a higher CD4 count than men (23).   Fortunately, with large 
scale HIV counselling and testing campaigns, coupled with a comprehensive 
management strategy for those with HIV since 2007, the epidemic is slowly changing 
in South Africa (24).  Hence, more than half of patients in this study were on 
antiretroviral therapy prior to liver biopsy.  Indirectly, this may also be a factor 
accounting for the major finding in this study of a high frequency of DILI.  
A total of 42.2% of patients in this cohort were clinicopathologically determined to 
have a DILI.   A clinical correlation was noted between the liver enzyme profiles and 
the histological patterns of DILI we observed.  Drug- related steatohepatitis and 
granulomatous inflammation was only observed in a small number of patients.  
Patients with grade 1 hepatotoxicity were invariably noted on biopsy to have what 
was described as drug related or adaptive changes.   
Univariate analysis suggested cotrimoxazole, HAART and herbal medications were 
most frequently associated with DILI, although the number of patients with herbal 
medications was decidedly small.  At first it appears anomalous that anti-TB drugs, 
well known for their hepatotoxic potential, were not overtly associated with DILI.  












liver biopsy in patients with a suspected anti-TB drug DILI.   In such patients, prompt 
withdrawal of anti-TB drugs, the exclusion of other causative factors and a 
subsequent resolution of an abnormal liver enzyme profile, is a diagnosis by 
inference of an anti-TB drug DILI and management would not generally include a 
liver biopsy.   
 
DILI is a well-recognized complication in HIV positive patients, given their potential 
use of HAART, anti-TB therapy and other antimicrobials such as cotrimoxazole, both 
for prophylactic and therapeutic purposes.   Hepatotoxicity related to HAART is 
reported to range from 2 – 37% depending on the regimen used, as well as the 
definition of hepatotoxicity utilized in that assessment  (25).   In South Africa, HAART 
hepatotoxicity has also been noted as a frequent observation in clinical HIV practice, 
particularly in the setting of TB-HIV co-infection and conferred a 35% 3-month 
mortality risk (26, 27).    
 
In our study, the majority of patients with steatohepatitis related DILI were using 
stavudine and/or didanosine as part of their HAART regimen.  This is 
understandable given their potential mitochondrial toxicity (28).  Owing to this and 
other toxicity, the use of didanosine has declined and is used less frequently.  
Furthermore, in 2010, tenofovir replaced as a first line NRTI in the public HAART 
programme in South Africa.   
 
The most frequent histological pattern of drug injury observed was a non-specific 
hepatitis and this corresponded with grade 2 hepatotoxicity.   In the multivariate 












with this pattern of injury.   A hepatocellular pattern of drug injury with these drugs is 
well described (29, 30).  Although not specifically assessed in our study, recent data 
from Tanzania, another middle or low income country, noted an increased risk of 
efavirenz related DILI when used concomitantly with anti-TB drugs, particularly 
rifampicin.  Another possible factor was polymorphisms of CYP2B6 (31).  
  
Cholestatic and mixed cholestatic-hepatitic injuries were strongly associated with 
cotrimoxazole, as was female gender.  Female gender is generally thought to be 
associated with an increased risk of DILI, although this has recently been questioned 
(32).   Cotrimoxazole has been associated with a variety of histological patterns of 
DILI although its commonest association is with cholestatic and ductopenic injuries.   
Cotrimoxazole hepatotoxicity in patients with HIV/AIDS was recognized early on in 
the HIV pandemic as a potential problem (33).  In this study, it was the drug almost 
exclusively associated with patients who had a ductopenic or vanishing bile duct 
syndrome DILI.  In these patients, the injury developed after high dose cotrimoxazole 
use in the treatment of either Pneumocystis jirovecii pneumonia or cerebral 
toxoplasmosis, rather than those using it for purposes of prophylaxis.  This suggests 
that the risk of a ductopenic injury in this clinical setting may be a dose-related 
phenomenon. 
 
The question as to whether drug-induced liver injuries occur at a greater frequency in 
HIV positive patients than they do in HIV negative patients, is unclear although 
previous studies suggested that the frequency of drug allergy or hypersensitivity in 
patients with HIV ranges from 3% to 20%, much higher than the general population 












treatment in HIV/AIDS is associated with hypersensitivity reactions in 3% to 5% of 
HIV-negative patients (19).    
 
Co-infection with hepatitis B or C is known to increase the risk of HAART 
hepatotoxicity (35).  The low background prevalence of hepatitis C in South Africa 
and in our study would limit the influence of this effect.  However, a surprising finding 
was the lack of association between drug injury and HBsAg in our study.    It likely 
relates to this not being a broad population based study looking at all HIV/AIDS 
patients with hepatotoxicity but rather only those who had a liver biopsy.   
Furthermore, a local study previously noted an association with HAART 
hepatotoxicity and hepatitis B, although at a risk lower than populations in high 
income countries (27).  Another factor could be that for a period prior to the 
widespread availability of tenofovir in the public program, patients were uniformly 
tested for HBsAg.  Those co-infected were defaulted to tenofovir/lamivudine based 
HAART automatically and at a higher CD4 cell count level.  This may have 
ameliorated the hepatotoxicity risk of hepatitis B in our population (36).   Equally a 
lack of association with regular alcohol use and all patterns of DILI was observed, 
possibly due to the relatively low frequency of alcohol use in this cohort.  In addition, 
more men than woman used alcohol and a trend towards female gender with some 
DILI histological subtypes was noted in multivariate analysis. 
 
Efavirenz was strongly associated with submassive necrosis as was younger age 
and a CD4 cell count >200 cells/mm3, which mirrors the reported risks for nevirapine 
associated DILI (37, 38).  Although nevirapine was associated with a non-specific 












necrosis is explained by the small number of patients using nevirapine as the NNRTI 
in their HAART regimen (21 nevirapine vs. 120  efavirenz).  This is due, in part, to a 
reduction in the use of nevirapine since 2010 in the public HAART program in South 
Africa, given newer data of the low teratogenic risk of efavirenz in pregnancy.  As 
with anti-TB drugs, bias in not biopsying patients with suspected nevirapine 
hepatotoxicity given its characteristic pattern, would be an additional explanation for 
this observation.  
The 29% frequency of granulomatous inflammation predominantly due to 
Mycobacterium tuberculosis in this study is not surprising and is similar to other 
studies (12, 39).  Mycobacterium avium complex, seen in only 3 patients, is 
surprisingly uncommon in our setting, although the reasons for this are not entirely 
clear (40).  Granulomas were largely non-necrotizing, a feature well recognized in 
patients with advanced HIV/AIDS and is due to a marked HIV associated immune 
compromise (41-43).  More than half of the patients fulfilled criteria for a TB immune 
reconstitution inflammatory syndrome (IRIS) affecting the liver (44).  This hepatic 
predominant type IRIS has not yet been described in the literature and poses a 
significant clinical challenge after initiating HAART, given that the differential 
diagnoses in this setting are wide.   
Little data on the histological features of hepatitis B in HIV positive patients exists 
(45).  In our study the age, gender and median ALT and AST levels did not differ 
between HBeAg positive and negative patients.  HBeAg negative patients had a 
significantly lower median CD4 cell count and HBV DNA viral load than the HBeAg 
positive patients.  Despite this, median histological necroinflammatory activity and 
fibrosis assessment did not differ in the 2 groups.  Overall, median ALT and AST 












relatively moderate necroinflammatory activity observed.  This may in part reflect the 
degree of HIV related immunosuppression.  One patient had fibrosing cholestatic 
hepatitis related to hepatitis B, a pattern described initially in the setting of liver 
transplantation and rarely in the setting of HIV-HBV co-infection (46). The presence 
of anti-HB core in two-thirds of those who were HBsAg negative highlights the 
endemic nature of hepatitis B in South Africa.  
Hepatitis C has low background prevalence in South Africa and this is reflected in 
the modest number of patients with hepatitis C co-infection, a factor that promotes 
hepatitis C related liver fibrosis.  Genotype 1a predominated (80%) and 40% of 
patients had advanced fibrosis/cirrhosis (≥F3), a feature frequently observed in co-
infected populations (6).   
Non alcohol related steatosis and steatohepatitis was observed in 19.3% of patients.  
Several other studies have made a similar observation (9, 12, 13).  NAFLD is a 
finding in up to a half of HIV patients with unexplained liver enzyme abnormalities 
(47, 48).  The reasons are likely multifactorial and include nutritional factors, HIV 
itself or insulin resistance related to antiretroviral therapy (47).  
In conclusion, we have demonstrated the wide range of liver pathology and disease 
encountered in a middle or low income country with a high HIV prevalence.  Our 
findings provide insight into the actual pathology that accounts for liver disease in 
this patient population in the clinical context of a low and middle income country.  
DILI, notably due to cotrimoxazole and HAART, are frequently encountered and 
complicate HIV management.  Hepatitis B co-infection, although frequent, does not 
pose a significant clinical problem.  However, the phenomenon of TB-IRIS involving 












area.    Given the need for an accurate and early diagnosis in patients with advanced 
HIV/AIDS presenting with liver disease, we would suggest liver biopsy is considered 
as early as is clinically warranted.  Liver biopsy together with careful clinico-
pathological assessment provides a useful tool in guiding management in these 
clinically complex patients.  However it should be recognized that given the burden 
of disease in South Africa it is unrealistic that liver biopsy will be widely available to 
all patients.   
Abbreviations 
NRTI, nucleoside reverse transcriptase inhibitors 
NNRTI, non- nucleoside reverse transcriptase inhibitors 
ERCP, Endoscopic retrograde cholangiopancreatography  















Table.1 Baseline characteristics of 301 patients at the time of liver biopsy  
Parameter N = 301 P-value 
Age (years)  
Males - n (%) 
   Age (years): Male: Female 
 
CD4 (cells/mm3) 
   CD4 Male: Female 
   CD4 <200 
   CD4<50 
HIV/AIDS* clinical stage, n (%): 
             1 
             2 
             3 
             4 
 
Ethnic group# – n (%) 
              Black 
              White 
              Mixed Ancestry 
              Asian/Indian 
 
Alcohol consumption – n (%) 
               Male: Female 
 
HBsAg positive – n (%) 
 
HCV antibody positive – n (%) 
      HCV PCR positive 
      Genotype 1a 
      Genotype 2 
      Genotype 3a 
 
Medication drug use§ – n (%) 
    Cotrimoxazole (BactrimR) 
    HAART 
    Anti-TB medication 
    Fluconazole 
    Herbal 
    Other¶ 
  34 (29-40) 
158 (52.4) 
  35 (31-41) : 33 (28-37) 
 
127 (52-260) 
118 (46-259):132 (55-270) 
201 (66.7) 
  70 (23.3) 
 
    1 (0.4) 
  53 (17.6) 





  35 (11.6) 
  35 (11.6) 
    2 (0.7) 
 
  75 (24.9) 
  56 (75) / 19 (25) 
 
  56 (18.6) 
 
  11 (3.7) 
  10 (3.3) 
    8 
    1 






  16 (5.3) 
  10 (3.3) 























The data is expressed as medians and interquartile ranges or numbers and percentages                                           
* World Health Organization clinical staging system for HIV/AIDS 
# Ethnic group is self-reported 
§ Medication use at or within 4 weeks of biopsy 














Table 2. Frequency of various HAART regimens used 
 
HAART regimen, n = 162     
 
 
  N (%) 
 
Nucleoside RT inhibitors  
     LAM/D4T 
     LAM/TDF 
     LAM/AZT 
     TDF/FTC 
     DDI/D4T 




   
  72 (46) 
  38 (24) 
  28 (18) 
  10 (6) 
    8 (5) 
    2 (1) 
 
Non-nucleoside RT inhibitors 
     Efavirenz 






  21 (15) 
 
Protease inhibitors 
      Lopinavir/Ritonavir 
      Atazanavir/Ritonavir 
      Amprenavir 
 
 
  21 (13) 
  
  18 (86) 
    2 (10)  
    1 (4) 
 
Abbreviations: RT, reverse transcriptase; LAM, Lamivudine; D4T, Stavudine; AZT, Azidothymidine; TDF, 























Table 3. Frequency of clinico-pathological findings 
Finding, n=301 Frequency – n (%) 
Drug induced liver injuries 
      Non-specific hepatitis 
      Cholestasis 
      Mixed hepatitis-cholestasis 
      Submassive necrosis 
      Ductopenia/vanishing bile duct  
      Steatohepatitis 
      Granulomatous (drug related) 
               127 (42.2) 
   51 (40.2) 
   20 (15.7) 
  25 (19.7) 
  13 (10.2) 
11 (8.6) 
  5 (4.0) 
  2 (1.6) 
 
Granulomatous inflammation     
Necrotizing/Non-necrotizing 
         Mycobacterium tuberculosis¶ 
         Mycobacterium avium complex* 
         Cryptococcosis§ 
         Drug 
TB-IRIS related#  
 
                 86 (29) 
                   7 (8)/79 (92) 
61 (71) 
    3 (3.5) 
    1 (1.1) 
    2 (2.3) 




                  56 (19) 
 
Steatosis/Steatohepatitis 
       Steatosis 
       Steatohepatitis    
 
                  58 (19.3) 
     42 (72.4) 
    16 (27.6) 
 
Alcoholic liver disease 
 
                 16 (5.3%) 
 
Hepatitis C (PCR positive) 
 
                 10 (3.3) 
 
Siderosis > grade 1(49) 
 
                 24 (8.0) 
 
Lymphoma 
 High grade B-cell/Hodgki ’s lymphoma  
 
                   7 (2.3) 




                   7 (2.3) 
 
Drug related/adaptive changes 
 
                   7 (2.3) 
 
Indeterminate findings  
 
                   5 (1.6)  
 
>1 pathological finding  
 
                 49 (16.2) 
 
¶ Mycobacterium tuberculosis cultured from liver or other fluid/tissue 
* Mycobacterium avium complex cultured from liver or other fluid/tissue 
§ Cryptococcus neoformans cultured from liver tissue 












Table 4. Liver profiles of the various histological patterns of DILI 














































 193 (110-318) 
 

































 660 (244-1288) 
 














       255 (48-357) 
 






































 75 (50-324) 
 





The data is expressed as medians and interquartile ranges                            
Abbreviations: ALT, alanine aminotransferase; AST aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase 
¶ Grading of hepatotoxicity by ALT level based on median ALT: grade 1, (1.0-2.5 × ULN); grade 2, (2.6–5.0 × ULN); grade 3,(5.1–10 × ULN); grade 4, >10×ULN       


















        DILI, n (%) 
          N = 127 
 
   Non-DILI, n (%) 
     N = 174 
 








  35 (30-40) 
 







   78 (45) 
   







 118 (68) 
 







   72 (41) 
 







   84 (48) 
 







   71 (40.8) 
 





  8 (6) 
 
    2 (1.1) 
 





  9 (7) 
 
     7 (4) 
 
1.79 (0.65-4.96)        0.257 
 
* The data is expressed as medians and interquartile ranges 






















Table 6. Multivariate Analysis of Clinical, Demographic and Drug Specific Factors associated with a specific histological pattern of DILI# 
 
 







        Non-specific 
            hepatitis 
 
   OR(95%CI)      P-value 
 
         Cholestatic 
 
 
 OR(95%CI)       P-value 
 
    Mixed cholestatic 
            hepatitic 
 
OR(95%CI)           P-value 
 
        Submassive 
           necrosis 
 
OR(95%CI)        P-value 
 
     VBDS/Ductopenia 
 
 








 1.1 (0.58-2.22)       0.7 
 
 3.25 (1.08-9.72)          0.03 
 
0.95 (0.38–2.4)          0.92 
 
1.36 (0.37–4.88)    0.63 
 





1.07 (0.54-2.13)       0.8 
 
1.46 (0.47-4.49)           0.50 
 
1.53 (0.56–4.13)        0.39 
 
0.21 (0.06–0.78)    0.012 
 





 0.6 (0.24-1.45)        0.15 
 
1.28 (0.36–4.58)          0.69 
 
0.8 (0.25–2.67)          0.74 
 
1.22 (0.27– 5.36)    0.79 
 




0.6 (0.23-1.51)         0.28 
 
0.29 (0.04-4.58)           0.24 
 
0.17 (0.03–1.31)        0.08 
 
0.36 (0.04–3.04)     0.35 
    
                   NA  
 
 
  Cotrimoxazole 
 
 
3.82 (1.82-8.0)         0.001 
 
  7.05 (2.50–19.89)     <0.001 
 
3.99 (1.57–10.17)     0.003 
 
1.16 (0.22–5.95)     0.85 
 




4.3 (1.92-9.83)       <0.001 
 
0.89 (0.34-2.39)           0.88 
 
2.69 (0.86–11.5)       0.07 
 
10.46 (2.70– 40.5)   <0.001 
 





9.6 (2.25-40.86)       0.002 
 
1.91 (0.21–18.01)        0.56 
 
1.25 (0.14–11.07)       0.50 
 
1.47 (0.13– 6.49)     0.75 
 





1.9 (0.18-20.51)      0.57 
 
2.93 (0.72-11.84)         0.13 
 
            NA 
 
             NA 
 





8.1 (2.4-27.81)       <0.001 
       
             NA 
 
3.53 (0.85–14.61)      0.08 
 
4.27 (0.62–29.45)    0.13 
                   
                  NA  
 
# Steatohepatitis/Granulomatous patterns and fluconazole/herbal medication not included given the low frequencies of their occurrence  

















HBeAg-positive, n - 32 
 
HBeAg-negative, n - 24 
 





       34 (30-39) 
 
 33 (29-39) 
 
  0.49 
 
Male gender n (%) 
 
 
       24 (75) 
 
            13 (54) 
 





     172 (79-332) 
 
 105 (51-163) 
 





       12 (9-21) 
 
 22 (10-85) 
 






     154 (84-467) 
 
  170 (109-417) 
 






     155 (78-512) 
 
 216 (113-387) 
 
  0.5 
 





         7.9 (5.1-8.5) 
 
     5.9 (4.4-6.9) 
 















        2 (1-3) 
 
             2 (2-3) 
 
  0.8 
 
The data is expressed as medians and interquartile ranges 
Abbreviations (laboratory reference range): Total BR, Total bilirubin (0-21µmol/L); ALT, alanine 
aminotransferase (5-40U/L); AST, aspartate aminotransferase (5-40 U/L) 
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should be separated by two hard returns. Do not use hard returns within 
paragraphs. Do not use the program's indenting or margin-setting features; 
these will be added during typesetting. 
 Submissions may include the names of any reviewers the authors wish to 
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 Requests to exclude an Associate Editor can only be considered if a clear 
conflict of interest is explained in the cover letter.  
Manuscript Organization 
All elements of a manuscript should be double-spaced, and all pages must be 
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No more than 120 characters, not including spaces between words. The use of 
acronyms and abbreviations should be avoided. The species used for work with 
experimental animals must be indicated in the title. 
 
Author Names 
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Name, address, telephone number, fax number, and e-mail address for the 
corresponding author.  
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results, and conclusions. Acronyms and abbreviations must be defined in the 
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Do not include a heading. Provide the minimum background information that will 




Provide a level of detail such that another investigator could repeat the work; for 




For reports of research using human subjects, provide assurance that (a) informed 
consent in writing was obtained from each patient and (b) the study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in 
a priori approval by the appropriate institutional review committee. Refer to individual 
patients by number, not by initials. HEPATOLOGY will only accept papers for review 
from liver transplant centers that explicitly state that no donor organs were obtained 
from executed prisoners or other institutionalized persons. Papers without such 
explicit statements will be returned without review. 
Animal Experimentation 
In studies involving animal experimentation, provide assurance that all animals 
received humane care according to the criteria outlined in the "Guide for the Care 
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Genetic Sequence Data 
In papers reporting a novel DNA or amino acid sequence, verify that the data have 
been or will be submitted either to GenBank or EMBL, and provide the accession 
number. This information need not accompany the initially submitted manuscript but 
must be available for inclusion in the final publication. Accession numbers appear as 
footnotes to the text or in the relevant figure legend. It is understood that authors 
publishing in HEPATOLOGY will make cloned DNA, hybridomas, mutant animals, 
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manuscript may only be electronically published and available to HEPATOLOGY 
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Manufacturers 
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Randomized controlled trials should be presented according to the CONSORT 
guidelines (JAMA 2001;285:1987-1991 or http://www.consort-statement.org ). 
Authors must provide the CONSORT checklist (found at 
http://mc.manuscriptcentral.com/hep , under Instructions and Forms) with a diagram 
that illustrates the progress of patients through the trial, including recruitment, 
enrollment, randomization, withdrawal and completion, and a detailed description of 












guidelines or do not include the CONSORT checklist at the time of submission will 
not be reviewed for publication.  
All clinical trials should be registered in order to be published in HEPATOLOGY.  
RESULTS AND DISCUSSION 
 
These two sections must be separate. Present the major findings of the study in 
graphic form if practicable. Do not illustrate minor details if their message is 
conveyed adequately by simple descriptive text. Mention all tables and figures. In the 
discussion, concisely present the implications of the new findings for the field as a 
whole, minimizing reiteration of the results, avoiding repetition of material in the 
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parentheses, other material (manuscripts submitted, unpublished data, personal 
communications, and the like) as in the following example: (Chercheur X, 
unpublished data). If the owner of the unpublished data or personal communication 
is not an author of the manuscript under review, a signed statement is required 
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2. HIV LIVER BIOPSIES DATA CAPTURE SHEET 
 
A. Patient and clinical information 
1. Folder number and Hospital: _____________________________________________   
2. Age : __________________________________________________________________ 
3. Gender : _______________________________________________________________ 
4. Date of biopsy: __________________________________________________________ 
5. Name & Surname: 
_______________________________________________________________________ 
6. History of alcohol use :   
_______________________________________________________________________ 
7. WHO HIV/AIDS clinical stage  : 
_______________________________________________________________________ 




B.  Investigations 
9. CD4 count (time of biopsy) : 
_______________________________________________________________________ 
10. HIV viral load : 
_______________________________________________________________________ 
11. Hep B status :                 
s-antigen : __________________________  core IgM : ________core IgG______        
e-antigen : __________________________ e-antibody: _____________________  
     HBV DNA viral load: __________________________________________________       
12. Hep C Antibody :    _______________________________________________________ 
Hep C PCR & genotype : ________________  Hep C viral load :_____________ 
13. Virology – other :            
Hep A IgM____________________         IgG _________________________   
CMV IgM____________IgG______________PCR______________________   
EBV EBna____________IgG______________PCR______________________      
Herpes simplex IgM____________________IgG______________________ 
14. Liver function tests (at biopsy, latest available)            
TPr____  _____  _____       Albumin_____  _____  _____     TBr_____   _____    ______ 
CBr____  _____   _____    AST______    ______  ______     ALT_____   ______   
ALP____   _____    _____ GGT______   ______  ______    INR_____    ______  ____ 
Hb  _____  _____  ______ WCC______  ______  ______    Plts______  _______  _____ 




























C.  Treatment 
a.  HAART :                  
(i) Drugs :  (a) NRTI’s :____________________________________________________
    (b) NNRTI’s : __________________________________________________                                
(c) PI’s : ______________________________________________________        
(ii) Duration : 
_______________________________________________________________________
_______________________________________________________________________ 
(iii) Date, if stopped, prior to biopsy : ______________________________________ 
18.  TB drugs                            
(i)  Regimen 1 or 2 :______________________________________________________  
(ii) Date started : ________________________________________________________ 




19.  Additional drugs                
(a) Cotrimoxazole (including dose) : _____________________________________       
Date, if stopped, prior to biopsy:______________________________________      
(b) Fluconazole (including dose) : ________________________________________
       Date, if stopped, prior to biopsy: ______________________________________ 























D. Liver biopsy information
21. Liver biopsy
(i) Specimen number : ___________________________________________________





22. (iii) Final diagnosis: (eg. drug induced hepatitis, drug induced cholestasis, mixed, viral 
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